{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T16:30:03Z","timestamp":1794846603858,"version":"4.9.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100019418","name":"NIHR BRC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019418","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.eururo.2025.07.007","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T03:30:34Z","timestamp":1761190234000},"page":"71-79","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Exploring Factors Associated with Late Urinary Toxicity After Prostate Stereotactic Body Radiotherapy: Findings from the PACE-B Study"],"prefix":"10.1016","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-2166-2938","authenticated-orcid":false,"given":"Ragu","family":"Ratnakumaran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas H.","family":"Brand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archana","family":"Sasitharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Mohajer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Hinder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asadullah","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hira","family":"Mayet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Loblaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"van As","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison C.","family":"Tree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2025.07.007_b0005","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.eururo.2019.08.005","article-title":"Recent global patterns in prostate cancer incidence and mortality rates","volume":"77","author":"Culp","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.07.007_b0010","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.eururo.2025.07.007_b0015","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","article-title":"Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"388","author":"Hamdy","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.07.007_b0020","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1001\/jamaoncol.2023.4267","article-title":"Increasing use of shorter-course radiotherapy for prostate cancer","volume":"9","author":"Yu","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2025.07.007_b0025","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.prro.2018.08.002","article-title":"Hypofractionated radiation therapy for localized prostate cancer: executive summary of an ASTRO, ASCO, and AUA evidence-based guideline","volume":"8","author":"Morgan","year":"2018","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.eururo.2025.07.007_b0030","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","article-title":"Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer","volume":"391","author":"van As","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.07.007_b0035","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/S1470-2045(22)00517-4","article-title":"Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial","volume":"23","author":"Tree","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.07.007_b0040","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2025.07.007_b0045","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ijrobp.2021.06.037","article-title":"Radiation dose to the intraprostatic urethra correlates strongly with urinary toxicity after prostate stereotactic body radiation therapy: a combined analysis of 23 prospective clinical trials","volume":"112","author":"Leeman","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2025.07.007_b0050","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.radonc.2021.12.027","article-title":"Urethral and bladder dose-effect relations for late genitourinary toxicity following external beam radiotherapy for prostate cancer in the FLAME trial","volume":"167","author":"Groen","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.eururo.2025.07.007_b0055","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.eururo.2013.02.001","article-title":"Patterns and predictors of amelioration of genitourinary toxicity after high-dose intensity-modulated radiation therapy for localized prostate cancer: implications for defining postradiotherapy urinary toxicity","volume":"64","author":"Ghadjar","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.07.007_b0060","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ijrobp.2009.07.1680","article-title":"Urinary obstruction in prostate cancer patients from the Dutch trial (68 Gy vs. 78 Gy): relationships with local dose, acute effects, and baseline characteristics","volume":"78","author":"Heemsbergen","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2025.07.007_b0065","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.radonc.2016.01.013","article-title":"Urinary bladder dose-response relationships for patient-reported genitourinary morbidity domains following prostate cancer radiotherapy","volume":"119","author":"Thor","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.eururo.2025.07.007_b0070","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.radonc.2014.06.009","article-title":"Dosimetric and patient correlates of quality of life after prostate stereotactic ablative radiotherapy","volume":"112","author":"Elias","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.eururo.2025.07.007_b0075","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13014-015-0351-6","article-title":"Hematuria following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer","volume":"10","author":"Gurka","year":"2015","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.eururo.2025.07.007_b0080","doi-asserted-by":"crossref","first-page":"e465","DOI":"10.1016\/j.prro.2015.02.001","article-title":"Dose-volume analysis and the temporal nature of toxicity with stereotactic body radiation therapy for prostate cancer","volume":"5","author":"Seymour","year":"2015","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.eururo.2025.07.007_b0085","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3109\/0284186X.2015.1037011","article-title":"Late urinary toxicity modeling after stereotactic body radiotherapy (SBRT) in the definitive treatment of localized prostate cancer","volume":"55","author":"Kole","year":"2016","journal-title":"Acta Oncol"},{"key":"10.1016\/j.eururo.2025.07.007_b0090","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.radonc.2017.03.006","article-title":"Stereotactic ablative radiotherapy in the treatment of low and intermediate risk prostate cancer: is there an optimal dose?","volume":"123","author":"Helou","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.eururo.2025.07.007_b0095","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.radonc.2019.11.017","article-title":"Dosimetric predictors of toxicity and quality of life following prostate stereotactic ablative radiotherapy","volume":"144","author":"Alayed","year":"2020","journal-title":"Radiother Oncol"},{"issue":"3 Suppl","key":"10.1016\/j.eururo.2025.07.007_b0100","doi-asserted-by":"crossref","first-page":"S116","DOI":"10.1016\/j.ijrobp.2009.02.090","article-title":"Radiation dose-volume effects of the urinary bladder","volume":"76","author":"Viswanathan","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2025.07.007_b0105","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ijrobp.2020.09.054","article-title":"Prostate stereotactic body radiation therapy: an overview of toxicity and dose response","volume":"110","author":"Wang","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2025.07.007_b0110","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S1470-2045(19)30569-8","article-title":"Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial","volume":"20","author":"Brand","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.07.007_b0115","unstructured":"Sanda M, Wei JT, Litwin MS. Scoring instructions for the Expanded Prostate Cancer Index Composite Short Form (EPIC-26) 2002. https:\/\/medicine.umich.edu\/sites\/default\/files\/content\/downloads\/Scoring%20Instrutions%20for%20the%20EPIC%2026.pdf."},{"key":"10.1016\/j.eururo.2025.07.007_b0120","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-032795","article-title":"Determining the minimal important differences in the International Prostate Symptom Score and Overactive Bladder Questionnaire: results from an observational cohort study in Dutch primary care","volume":"9","author":"Blanker","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.eururo.2025.07.007_b0125","article-title":"Developing and validating a simple urethra surrogate model to facilitate dosimetric analysis to predict genitourinary toxicity","volume":"46","author":"Ratnakumaran","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.eururo.2025.07.007_b0130","series-title":"Double\/debiased machine learning for treatment and structural parameters","author":"Chernozhukov","year":"2018"},{"key":"10.1016\/j.eururo.2025.07.007_b0135","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","article-title":"Index for rating diagnostic tests","volume":"3","author":"Youden","year":"1950","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2025.07.007_b0140","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.h2464","article-title":"How to read a receiver operating characteristic curve","volume":"350","author":"Sedgwick","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2025.07.007_b0145","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.3390\/cancers15041288","article-title":"The association between acute and late genitourinary and gastrointestinal toxicities: an analysis of the PACE B study","volume":"15","author":"Ratnakumaran","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.eururo.2025.07.007_b0150","doi-asserted-by":"crossref","unstructured":"Ratnakumaran R, Sasitharan A, Khan A, et al. Dosimetric comparison of CyberKnife and conventional LINAC prostate stereotactic body radiation therapy plans: analysis of the PACE-B study. Int J Radiat Oncol Biol Phys. In press. https:\/\/doi.org\/10.1016\/j.ijrobp.2025.01.014.","DOI":"10.1016\/j.ijrobp.2025.01.014"},{"key":"10.1016\/j.eururo.2025.07.007_b0155","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1007\/s00345-023-04579-6","article-title":"State of the art and future challenges of urethra-sparing stereotactic body radiotherapy for prostate cancer: a systematic review of literature","volume":"41","author":"Le Guevelou","year":"2023","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2025.07.007_b0160","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.ijrobp.2023.03.057","article-title":"Every-other-day versus once-a-week urethra-sparing prostate stereotactic body radiation therapy: 5-year results of a randomized phase 2 trial","volume":"117","author":"Zilli","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2025.07.007_b0165","article-title":"Urethra-sparing prostate cancer radiotherapy: current practices and future insights from an international survey","volume":"51","author":"Gu\u00e9velou","year":"2025","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.eururo.2025.07.007_b0170","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.prro.2015.01.006","article-title":"Dosimetric parameters predict short-term quality-of-life outcomes for patients receiving stereotactic body radiation therapy for prostate cancer","volume":"5","author":"Gomez","year":"2015","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.eururo.2025.07.007_b0175","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.ijrobp.2023.10.015","volume":"118","author":"Neilsen","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2025.07.007_b0180","article-title":"Stereotactic body radiation therapy for prostate cancer after surgical treatment of prostatic obstruction: impact on urinary morbidity and mitigation strategies","volume":"45","author":"Huck","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.eururo.2025.07.007_b0185","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.radonc.2016.03.007","article-title":"Quantification of dose uncertainties in cumulated dose estimation compared to planned dose in prostate IMRT","volume":"119","author":"Nassef","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.eururo.2025.07.007_b0190","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1120\/jacmp.v17i6.6207","article-title":"Dosimetric and volumetric changes in the rectum and bladder in patients receiving CBCT-guided prostate IMRT: analysis based on daily CBCT dose calculation","volume":"17","author":"Pearson","year":"2016","journal-title":"J Appl Clin Med Phys"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283825003975?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283825003975?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T05:36:22Z","timestamp":1773898582000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283825003975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0302283825003975"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2025.07.007","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring Factors Associated with Late Urinary Toxicity After Prostate Stereotactic Body Radiotherapy: Findings from the PACE-B Study","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2025.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}